AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06052696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Trial: NCT04803955
Drug: 16mg，KB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16mg,Q8h±3min,Day1-Day7
Trial: NCT04803955
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16mg,Q8h±3min,Day1-Day7
Trial: NCT06140537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet orally daily
Trial: NCT05395260
Drug: FL-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FL-101 200mg IV
Trial: NCT05131555
Drug: Placebo: Placebo + exercise training.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo Exercise training: Interval-based cycling exercise
Trial: NCT05131555
Drug: H1 blockade: H1 receptor antagonist + exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
Trial: NCT05131555
Drug: H2 Blockade: H2 receptor antagonist + exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
Trial: NCT05099159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily
Trial: NCT05040360
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05389215
Drug: DWN12088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWN12088 Xmg Tablet (BID)
Trial: NCT05389215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0mg Tablet (BID)
Trial: NCT03134131
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
Trial: NCT06304779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
Trial: NCT04088591
Drug: Ascorbic Acid 500Mg/Ml Inj
RxNorm normalized name: ASCORBIC ACID 500MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
Trial: NCT05556577
Drug: investigational medicine product (IMP)
RxNorm normalized name: Medicaine Sting Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational medicine product (IMP) received at SURMOUNT-CN trial
Trial: NCT05860465
Drug: SPH4336 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
Trial: NCT05860465
Drug: SPH4336 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
Trial: NCT04650217
Drug: Carbidopa/levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose.
Trial: NCT04650217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa matched placebo
Trial: NCT06209879
Drug: SYSTANE™ Hydration Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
Trial: NCT05178862
Drug: Echinocandin
RxNorm normalized name: Echinocandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous echinocandin
Trial: NCT05849519
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group was treated with conventional treatment
Trial: NCT05687513
Drug: Yisui granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yisui granule
Trial: NCT05687513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05547789
Drug: non steroidal anti inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of non steroidal anti inflammatory drugs on macular changes
Trial: NCT04826016
Drug: POL6326
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Trial: NCT05126628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 tablets q.d. for 14 days
Trial: NCT06429566
Drug: GB001 recombinant peptide spray low dose group、high dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
Trial: NCT06429566
Drug: GB001 recombinant peptide spray placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
Trial: NCT06635681
Drug: combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease.
Trial: NCT05104970
Drug: SunnyD insta ampoule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 200000 IU insta ampoule
Trial: NCT05104970
Drug: Placebo SunnyD insta ampoule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil
Trial: NCT06580236
Drug: B11-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT05559645
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of DZD9008 200mg
Trial: NCT05559645
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of DZD9008 300mg
Trial: NCT04684121
Drug: Granexin® gel (200 μM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
Trial: NCT04684121
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
Trial: NCT06249932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Trial: NCT06647550
Drug: HD-6277 100mg
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT06647550
Drug: HD-6277 50mg
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT06647550
Drug: HD-6277 25mg
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT06647550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT05050656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets identical to duloxetine tablets
Trial: NCT05433597
Drug: TNF
RxNorm normalized name: TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
Trial: NCT05433597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
Trial: NCT04724967
Drug: CeraVe Hydrating Cleanser
RxNorm normalized name: CeraVe Hydrating Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cleanser applied twice a day for 28 days
Trial: NCT04724967
Drug: CeraVe Moisturizing Cream
RxNorm normalized name: CeraVe Moisturizing Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream applied twice a day for 28 days
Trial: NCT05346653
Drug: SGLT2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dapagliflozin (10 mg daily)
Trial: NCT06039358
Drug: Cellulose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Trial: NCT04878913
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 was administered in the VP-C21-006 trial
Trial: NCT04878913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered in the VP-C21-006 trial
Trial: NCT04897854
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
Trial: NCT06551259
Drug: physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline
Trial: NCT05800275
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m², twice daily on days 1-14 of each 21-day cycle
Trial: NCT06732232
Drug: CD19/CD20/BCMA CAR-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19/CD20/BCMA CAR T therapy
Trial: NCT05591027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
Trial: NCT04494126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
Trial: NCT05282797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT05134181
Drug: sacroiliac joint injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied
Trial: NCT05927259
Drug: n acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
Trial: NCT05150938
Drug: Low molecular weight heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Trial: NCT05150938
Drug: vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Trial: NCT05927259
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stabilization and antidotes
Trial: NCT04620252
Drug: Tricalcium phosphate supplement
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tricalcium phosphate supplement, chewed for 30 seconds.
Trial: NCT04620252
Drug: Calcium carbonate supplement
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable calcium carbonate supplement, chewed for 30 seconds.
Trial: NCT04620252
Drug: Calcium citrate supplement
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium Phosphate (DB11348)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable calcium citrate supplement, chewed for 30 seconds.
Trial: NCT04620252
Drug: Calcium carbonate supplement and fluoride mouthwash
RxNorm normalized name: calcium carbonate / sodium fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Trial: NCT04620252
Drug: Calcium citrate supplement and fluoride mouthwash
RxNorm normalized name: sodium fluoride Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Trial: NCT04736628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06548932
Drug: GZR33 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose
Trial: NCT06548932
Drug: GZR101 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose
Trial: NCT06548932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose
Trial: NCT06200883
Drug: Placebo oral vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
Trial: NCT06200883
Drug: Choline Bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
Trial: NCT05830071
Drug: CHF5993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB 100/6/12.5 μg pMDI
Trial: NCT05830071
Drug: CHF5259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB 12.5 μg pMDI
Trial: NCT05830071
Drug: CHF5993 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pMDI
Trial: NCT06366230
Drug: Urea in the dialysate
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
Trial: NCT05451654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Trial: NCT05451654
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Trial: NCT06580288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg or 20mg
Trial: NCT06485817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Trial: NCT05788497
Drug: Hemorrane plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
Trial: NCT05788497
Drug: Hemorrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemorrane 10 mg/g rectal ointment
Trial: NCT05788497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal ointment
Trial: NCT06564441
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine
Trial: NCT04677972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo containing excipients
Trial: NCT05387577
Drug: Estradiol Tablets
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
Trial: NCT05387577
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol patch therapy for 8 weeks
Trial: NCT05387577
Drug: Estradiol Tablets
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral estradiol 1 mg BID for 8 weeks
Trial: NCT04861077
Drug: [18F]FMISO-PET with contrast-enhanced MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
Trial: NCT06520618
Drug: Qing Re He Ji
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Qing Re He Ji
Trial: NCT06520618
Drug: Shuanghuanglian Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Shuanghuanglian Oral Liquid
Trial: NCT04731779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Trial: NCT06490562
Drug: PDCy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD